CORPET Coriolus: Veterinary Mushroom Product Profile

CORPET Coriolus is a named branded product for Dogs and cats for the tablet presentation; the manufacturer also offers a horse/pony powder; manufacturer positioning must be kept separate from independent clinical evidence.

Film-coated 500 mg tablets for small animals and a separate 750 g powder presentation for horses and ponies. Intended species: Dogs and cats for the tablet presentation; the manufacturer also offers a horse/pony powder.

Each tablet contains 500 mg Coriolus versicolor biomass powder comprising mycelium and primordia. Additional tablet ingredients listed by the manufacturer are microcrystalline cellulose, silica, and vegetable magnesium salts. The manufacturer also publishes an in-vitro enzyme and constituent analysis.

MRL presents CORPET as organic mushroom biomass produced under controlled conditions and used for immune support in small animals, including supportive and palliative contexts. Manufacturing standardization and enzyme analyses characterize the product but do not demonstrate a cancer-treatment effect.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

The official site provides product composition, manufacturing description, and animal-health discussion. No randomized controlled canine or feline oncology trial of CORPET demonstrating tumor response or survival was identified in the reviewed official sources. Evidence involving purified PSK or PSP, human oncology, or another Coriolus extract cannot be assumed equivalent to mycelium-and-primordia biomass.

Review mushroom allergy, gastrointestinal tolerance, autoimmune disease, immunosuppressive or immune-directed therapy, anticoagulants, surgery, pregnancy, and organ dysfunction. Species, form, strength, substrate, and extraction differ across mushroom products. Tablet binders and the distinct equine powder must not be conflated. Use the veterinarian and current label, not a dose from another extract.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

The manufacturer describes CORPET as a food supplement produced to food-grade GMP standards. It is not presented as an EU-authorized veterinary medicinal product, and no such cancer-treatment authorization was identified. Organic certification and GMP relate to defined production claims, not clinical efficacy.

European Union; International distributor network

Record the exact small-animal tablet product, lot, expiry, start date, and supportive goal. Follow appetite, vomiting, diarrhea, stool, itching, swelling, energy, weight, and treatment adherence. Maintain objective tumor and toxicity monitoring. If the product changes, reassess identity rather than assuming equivalence because the mushroom species name is unchanged.